《大行報告》富瑞料名創優品(09896.HK)第三財季經調整純利增246% 評級「買入」
富瑞發表報告,預計名創優品(09896.HK)截至今年3月底止第三財季海外業務將繼續保持強勁增長;內地市場方面,該行指觀察到持續的復甦勢頭,但由於季節性原因,3月份的整體銷售比春節稍爲放緩。
該行估計第三財季毛利率將按年增長7.3個百分點,但由於海外市場的銷售貢獻較小,按季則下降2.5個百分點。同時預計經調整純利將增長246%,至3.97億元人民幣,至於銷售額增長23%。維持其「買入」評級及目標價44.7元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.